A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

Summary

The purpose of the first-in-human (FIH) study is to obtain safety, tolerability, and pharmacokinetic information on SAR442501 in a healthy adult volunteer population using an integrated single ascending dose (SAD)-multiple ascending dose (MAD) parallel cohort study design.

Timeline

Start

2020-11-18

Primary completion

2022-01-12

Completion

2022-01-12

Drugs

Indications